Last reviewed · How we verify

Trastuzumab in combination with pertuzumab

Cancer Research UK · Phase 2 active Small molecule

Trastuzumab in combination with pertuzumab is a Small molecule drug developed by Cancer Research UK. It is currently in Phase 2 development. Also known as: Herceptin in combination with Perjeta.

At a glance

Generic nameTrastuzumab in combination with pertuzumab
Also known asHerceptin in combination with Perjeta
SponsorCancer Research UK
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Trastuzumab in combination with pertuzumab

What is Trastuzumab in combination with pertuzumab?

Trastuzumab in combination with pertuzumab is a Small molecule drug developed by Cancer Research UK.

Who makes Trastuzumab in combination with pertuzumab?

Trastuzumab in combination with pertuzumab is developed by Cancer Research UK (see full Cancer Research UK pipeline at /company/cancer-research-uk).

Is Trastuzumab in combination with pertuzumab also known as anything else?

Trastuzumab in combination with pertuzumab is also known as Herceptin in combination with Perjeta.

What development phase is Trastuzumab in combination with pertuzumab in?

Trastuzumab in combination with pertuzumab is in Phase 2.

Related